Business United States United States

RevMed’s Pancreatic Cancer Pill Priced Above $475K per Year

Bloomberg
Bloomberg
Aug 28, 2026 · 2:26 AM
0 views
RevMed’s Pancreatic Cancer Pill Priced Above $475K per Year
Revolution Medicines won US approval for a breakthrough pill that lengthens the lives of patients with advanced pancreatic cancer, a major advance against one of the hardest-to-treat tumor types. The once-daily drug carries a list price of more than $475,000 a year, making it one of the most expen…
Bloomberg
Continue Reading on Bloomberg
This article is aggregated from Bloomberg. Click below to read the full story.
Read Full Story
🔗 Share this story

Related Stories

📰
Install NewsTRP
Get news updates on your phone!